Nanjing Delova Biotech Co., Ltd.
PrivateLast Round
Series B
Extension
Apr 2, 2024
Total Funding Raised
$51.35M
Company Overview
Nanjing Delova Biotech Co., Ltd. operates in Healthcare & Life Sciences and is based in Nanjing. Its latest recorded funding round was a Series B Extension round in April 2024.
Nanjing Delova Biotech Co., Ltd. is a biopharmaceutical company that develops innovative, non-opioid analgesic drug formulations and long-acting injection technology platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanjing Delova Biotech Co., Ltd. Comparables
Compare Nanjing Delova Biotech Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hyloris Pharmaceuticals | 77% | |
| Heron Therapeutics Inc. | 77% | |
| Luye Pharma Group | 76% |
For institutional investors. Book with your work email.
Nanjing Delova Biotech Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 2, 2024 | ||||
| Series B | Jan 1, 2023 | ||||
| Series A | Jun 16, 2021 | ||||
| Pre Seed | Sep 14, 2020 | ||||
| Angel | Aug 25, 2017 |
For institutional investors. Book with your work email.
Nanjing Delova Biotech Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zhongqi Capital | Series B Extension |
| Legend Capital | Series A, Pre Seed |
| Shengjing Jiacheng | Series B Extension |
| MPC | Series A |
| Yingdi Capital | Angel, Pre Seed |
| Hyfinity Investments | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2024
$14M round with participation from Hyfinity Investments and Zhongqi Capital.
- Aug 25, 2017
Yingdi Capital participated in the Angel round.
For institutional investors. Book with your work email.
Nanjing Delova Biotech Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nanjing Delova Biotech Co., Ltd.'s valuation, stock price, and market status.
Is Nanjing Delova Biotech Co., Ltd. a public or private company?
Nanjing Delova Biotech Co., Ltd. is a private company.
What is the current stock price of Nanjing Delova Biotech Co., Ltd.?
Nanjing Delova Biotech Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Nanjing Delova Biotech Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanjing Delova Biotech Co., Ltd. worth (valuation)?
Valuation information for Nanjing Delova Biotech Co., Ltd. is not publicly available.
Can I buy Nanjing Delova Biotech Co., Ltd. stock?
Nanjing Delova Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanjing Delova Biotech Co., Ltd.'s last funding round?
Nanjing Delova Biotech Co., Ltd.'s most recent funding round was Series B Extension on April 2, 2024.
Who are the main investors in Nanjing Delova Biotech Co., Ltd.?
Key investors in Nanjing Delova Biotech Co., Ltd. include Legend Capital, MPC.
Will Nanjing Delova Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Nanjing Delova Biotech Co., Ltd..
How can I track Nanjing Delova Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Nanjing Delova Biotech Co., Ltd.'s shares on secondary markets.